S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Forecast, Price & News

$0.51
-0.07 (-12.07%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.50
$0.57
50-Day Range
$0.51
$1.36
52-Week Range
$0.50
$38.40
Volume
329,515 shs
Average Volume
223,326 shs
Market Capitalization
$2.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RDHL stock logo

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Price History

RDHL Stock News Headlines

Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
The Elites Are Waging War on Elon Musk — Here's Why…
Elon has helped unleash an opportunity that could create trillions in wealth for everyday Americans. So why does the deep state hate him for it?
RedHill Provides R&D Update
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings
8/17/2023
Today
9/29/2023
Next Earnings (Estimated)
12/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
Employees
113
Year Founded
N/A

Profitability

Net Income
$-71,670,000.00
Pretax Margin
-9.10%

Debt

Sales & Book Value

Annual Sales
$61.80 million
Book Value
($16.41) per share

Miscellaneous

Free Float
5,455,000
Market Cap
$2.98 million
Optionable
Optionable
Beta
2.00
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dror Ben-Asher (Age 57)
    Co-Founder, CEO & Director
    Comp: $734.59k
  • Mr. Gilead Raday MPhil (Age 48)
    MSc, Chief Operating Officer
    Comp: $445.38k
  • Mr. Adi Frish (Age 53)
    Chief Corp. & Bus. Devel. Officer
    Comp: $419.5k
  • Mr. Rick D. Scruggs (Age 63)
    Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
    Comp: $607.05k
  • Mr. Razi Ingber (Age 39)
    Chief Financial Officer
  • Ms. Alexandra Okmian
    Sr. Bus. Devel. & Investor Relations Mang.
  • Dr. Reza Fathi Ph.D. (Age 68)
    Sr. VP of R&D
  • Mr. Guy Goldberg (Age 47)
    Chief Bus. Officer
  • Dr. June S. Almenoff F.A.C.P. (Age 66)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Patricia Anderson B.Sc. RAC
    Sr. VP of Regulatory Affairs













RDHL Stock - Frequently Asked Questions

How have RDHL shares performed in 2023?

RedHill Biopharma's stock was trading at $5.6120 at the beginning of 2023. Since then, RDHL shares have decreased by 90.9% and is now trading at $0.51.
View the best growth stocks for 2023 here
.

Are investors shorting RedHill Biopharma?

RedHill Biopharma saw a drop in short interest in September. As of September 15th, there was short interest totaling 5,600 shares, a drop of 27.3% from the August 31st total of 7,700 shares. Based on an average daily volume of 393,700 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are short sold.
View RedHill Biopharma's Short Interest
.

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our RDHL earnings forecast
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Thursday, August, 17th. The biotechnology company reported $36.00 earnings per share (EPS) for the quarter. The biotechnology company earned $1.80 million during the quarter. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%.

When did RedHill Biopharma's stock split?

RedHill Biopharma's stock reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $0.51.

How much money does RedHill Biopharma make?

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $2.98 million and generates $61.80 million in revenue each year.

How many employees does RedHill Biopharma have?

The company employs 113 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -